MicroRNAs as clinical biomarkers? by Timothy G. Angelini & Costanza Emanueli
OPINION
published: 14 July 2015
doi: 10.3389/fgene.2015.00240
Frontiers in Genetics | www.frontiersin.org 1 July 2015 | Volume 6 | Article 240
Edited by:
Seyed Javad Mowla,
Tarbiat Modares University, Iran
Reviewed by:
Alessio Paone,
Sapienza University of Rome, Italy
Vijay Kumar Prajapati,





This article was submitted to
RNA,
a section of the journal
Frontiers in Genetics
Received: 08 May 2015
Accepted: 29 June 2015
Published: 14 July 2015
Citation:
Angelini TG and Emanueli C (2015)
MicroRNAs as clinical biomarkers?
Front. Genet. 6:240.
doi: 10.3389/fgene.2015.00240
MicroRNAs as clinical biomarkers?
Timothy G. Angelini 1 and Costanza Emanueli 2, 3*
1 Royal Surrey County Hospital, Guildford, UK, 2 Bristol Heart Institute, School of Clinical Sciences, University of Bristol,
Bristol, UK, 3National Heart and Lung Institute, Imperial College London, London, UK
Keywords: microRNAs, clinical biomarkers, exosomes, cardiac disease, myocardial infarction
A clinical biomarker has been defined as “any cellular, biochemical, molecular, or genetic alterations
by which a normal, abnormal, or simple biological process can be recognized or monitored”
(Drucker andKrapfenbauer, 2003; Rahim et al., 2015). Biomarkers are widely employed throughout
medicine on a day to day basis to diagnose, prognosticate, and predict outcomes of disease
and illness or even as guides of treatment. They can either be used as a standalone, or more
commonly, in conjunction with other test results. Moreover, biomarkers are often chosen as
“surrogate endpoints” in clinical trials. Biomarkers must fulfill certain criteria in order to make
it in to regular use in clinical practice. They must be specific to the condition that they are indicated
in, sensitive, and must be practical in terms of accessibility of the sample, ease of testing method
and provide information in which to guide clinical decisions. However, many biomarkers have
unsatisfactory specificity or are not as sensitive as they are made out to be. In addition, biomarkers
for some conditions are not yet available. Consequently, research in to novel biomarkers should be
encouraged.
Biomarkers can be classified in to different classes, one being the sources where they measured
from. In this respect, there are two distinct kinds of biomarker; intracellular, and extracellular
(which can be broken down into three further groups by means of sampling; invasive, minimally
invasive, and non-invasive). Examples of intracellular biomarkers include many of those used in
oncology, such as BRCA1/2 (Drooger et al., 2015), and estrogen receptor and hormone receptor
status in breast cancers (Yang et al., 2014), and BRAF genes in melanoma (Dar et al., 2015). For
these tests, the cells from the suspected tumor must be invasively sampled, often by core sampling,
or tissue scrapings. Extracellular biomarkers are often but not always linked with less invasive
sampling, for example the withdrawal of a peripheral venous blood sample or urine collection.
Examples are urine test for beta-human chorionic gonadotrophin (Chen et al., 2015) as an indicator
of pregnancy or prostate specific antigen (PSA) (Ravery, 1999) in a suspected prostate cancer case.
An exciting, but not yet conclusive, new area of research with the potential to derive new clinical
biomarkers has been into microRNAs (miRs). These short RNAmolecules were discovered in 1993
(Lee et al., 1993) in C. elegans and found present in human samples in 2000 (van Rooij, 2011).
From there, their love story with the biomedical community has seen a crescendo of enthusiasm
and they have been highly regarded as both novel therapeutic targets, and possible intracellular and
extracellular biomarkers. We might speculate that the reason behind this popularity is two-folds:
(1) The mode of action of miRs is relatively straightforward. MiRs do not contain any coding for
protein production (and hence they are classified as noncoding RNAs–ncRNAs) and each miR
is capable of post-translational regulation of the expression of a plethora of target messenger
RNAs (mRNAs), which it recognizes through the semi complementary nucleotide base-pairing
between its “seed sequence” (of just eight nucleotides) and one or more miR binding sites in
the 3′-untranslated region of the mRNA targeted (Jackson and Standart, 2007). The biology
of miR appears much simpler in comparison to, as an example, the long ncRNA that act via
multiple, with still largely un-clarified mechanisms, at transcriptional and post-transcriptional
levels, in the nucleus and the cytosol, and in cis and trans (Rinn and Chang, 2012). Moreover,
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miRs exist in a limited number, thought to be around 2000
in humans. However, miRs variants are still being discovered
through RNA-sequencing approaches.
(2) MiR are released by their producing cells in protected forms
allowing them to remain for long periods in biological fluids.
Moreover, miRs were initially believed to be tissue- and
even cell-specific. This led to the assumption that what was
found in the blood could sense the altered status of the cell
types or tissues that were supposed to produce such miR.
Now the concept of tissue/cell-specificity has been largely
dismissed and it is becoming clear that at best we can talk
of cell/tissue type enrichment for most, if not all, the known
miRs. Hence, it is quite unrealistic to think that, under most
clinical scenarios (with exceptions discussed later), the level
of a single miR measured in the whole plasma or serum can
be informative of a local slowly or relatively slowly evolving
condition, such as, a developing cancer (Washam et al.,
2013).
Circulating individual miRs, such as miR-21 (suggested to be
useful for the detection of various carcinomas) (Wang et al.,
2014; Wu et al., 2015), and circulating groups of miRs (such as
a serum miR classifier encompassing miR-29a, miR-29c, miR-
133a, miR-143, miR-145, miR-192, and miR-505, that has been
proposed to detect hepatocellular carcinoma) (Lin et al., 2015)
have been suggested as potential biomarkers that could be used in
cancer detection and staging, and to follow-up already diagnosed
cancer patients. However, in a recent article reporting the results
of the comparison among 15 previous reports on potential new
breast cancer biomarkers (Leinder et al., 2013) there was a scarce
overlap between results: “Of the 143 circulatingmiRNAs reported
to be differently regulated, 100 were supported by just 1 reference;
25 others had discordant results across publications and of the
remaining 18 miRs, 8 had fold changes too low to be confirmed.
Of the 10 concordant results, 9 were supported entirely by
publications from the same institution and had authors in
common” (Leinder et al., 2013; Witwer, 2015). This suggests
that further efforts are needed before miR-based biomarkers can
benefit cancer patients and that this could also apply to other
disease conditions. Cancer has been the first translational area
for miR work, closely followed by heart failure. Looking at both
clinical scenarios, we find a typical example of unspecificity:
circulating miR-21 has been proposed as a biomarker of both
prostate cancer (Egidi et al., 2013) and myocardial fibrosis (in
heart failure) (Thum et al., 2008). miR-21 is also the most
expressed miR by vascular endothelial cells (Greco and Martelli,
2014), which are the cells directly lining the circulating blood
and for this reason supposed to be the highest contributors to
miRs circulating in the peripheral blood (Greco and Martelli,
2014; Witwer, 2015). A miR such as this, amongst others that
are widely and highly expressed, might not be an ideal circulating
candidate biomarker, suggesting that miRs that are usually under
expressed, but upregulated under a particular condition could be
better suited to be employed in a diagnostic test. For example,
we recently found that miR-503 appears in the blood of diabetic
patients at the last stage of critical limb ischemia, i.e., when
they need an amputation (Caporali et al., 2011). It is possible
that circulatingmiR-503 could have a diagnostic/prognostic value
when measured at the earlier stages of the disease, however,
measuring miR-503 in a small leg muscle biopsy could provide
more reliable information.
There are areas where we believe that circulating miRs show
more promise and this is in the recognition of acute events,
such as myocardial infarct (MI), as well as in the surgical
setting, where time-restricted changes in miR expression have
been reported consistently. For examples, the heart (and skeletal
muscle)—enriched miR-1 has been noted to increase in patients
after open heart surgery, after MI or transcoronary ablation of
septal hypertrophy, an interventional procedure that mimics MI
(D’Alessandra et al., 2010; Widera et al., 2011; Liebetrau et al.,
2013; Nabialek et al., 2013). Diagnostic biomarkers are a key
part in emergency service provision and the rapid diagnosis, and
therefore treatment of patients with life threatening conditions.
One of the most widely used in the emergency department are
cardiac troponins (cTns: cTn-T and cTn-I) for the diagnosis of
MI. CTns are used in conjunction with other investigations, such
as electrocardiogram (ECG) changes, allowing, for example, to
determine whether a patient has had a “STEMI” type MI (with
ST segment Elevation by ECG). ECG cannot pick up non-STEMI
cases and here laboratory biomarkers are highly important
(Alpert et al., 2000). However, cTns are not always specific to
MI, they can be raised in patients with other cardiac conditions
and also after infection. In light of this, research into miRs as
potentially better biomarkers has been carried out showing time-
dependent increases in cardiac-enriched, ischemia-responsive
miRs in the blood of MI patients (D’Alessandra et al., 2010;
Nabialek et al., 2013). There has also been claim that miRs
can help differentiating the diagnosis of a STEMI compared
with other myocardial conditions, such as stable angina, non-
STEMI, and Takotsubo cardiomyopathy (Nabialek et al., 2013;
Ward et al., 2013; Jaguszewski et al., 2014). However, it is
yet to be demonstrated that miRs can replace cTns as routine
biomarkers used in the intensive coronary care unit, in depth
investigations of specificity and sensitivity in different cohorts
or patients are needed. Additionally, in the realm of emergency
medicine, sensitivity and specificity of miRs response in terms
of circulating changes are not the only issues, because the time
necessary by this putative biomarker to appear elevated in the
blood or another biological fluid is critical. Classically, cTns
take a few hours to increase in the blood after an MI. MiR-
1 has been proposed to go up earlier than cTns (Liebetrau
et al., 2013). However, for these comparisons, the time to
obtain the test results and the test reproducibility are big
obstacles yet to be overcome. Differently from high sensitive
cTns that today are measured by immune-enzymatic reactions
allowing for results to be obtained in around 20min, PCR-
based miR analyses are still quite time-consuming. Alternative
techniques for miR quantification have been proposed (Arata
et al., 2012) but they are far away from being commonly
employed by the scientific community, let alone the clinical
diagnostic lab. Additionally, in a clinical laboratory staff cannot
reason as in observational studies, where everybody is often
quite satisfied with saying “miR-1 is increased in the blood of
MI patients in comparisons to a control group.” Diagnostic use
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of miRs needs a different rigor and first of all a definition of
what the “normal” threshold of miR concentration is, above
which we can suspect in a patient who is experiencing a
heart attack. Scientists working in the miR field are aware
that this is not an easy task and by using PCR-based methods
quantitative differences between different studies are common.
In addition, the data normalization approaches are still debated
and interference by heparin (used in interventional procedures)
with the PCR reaction has been reported (Mayr et al., 2013),
even if protocol to nullify the “heparin effect” are adopted.
Alternative technologies can be developed, but this will require
further investment, time and validation efforts (Arata et al.,
2012).
In conclusion, We believe that miRs hold potential value
as clinical biomarkers, but, their journey to the diagnostic lab
is still long and needs improved approaches at multiple levels,
starting with technical refinement in the miR concentration
evaluation, the use of RNA-sequencing to possibly recognize
newmiRs that are better candidates (higher tissue/cell-specificity,
lower expression under healthy conditions etc.) and the use of
blood fractions potentially enriched in miRs (like exosomes and
microparticles) for diagnostic tests. It is also possible that miR
clusters have more specificity than single miRs. Moreover, miR
could be associated to other biomarkers to improve the diagnostic
power.
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